128 related articles for article (PubMed ID: 86358)
21. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
22. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
23. Benign hyperplasia of the human prostate exposed to steroid hormones in organ culture.
Harbitz TB; Falkanger B; Sander S
Acta Pathol Microbiol Scand Suppl; 1974; Suppl 248():89-93. PubMed ID: 4141577
[No Abstract] [Full Text] [Related]
24. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.
Daehlin L
Scand J Urol Nephrol Suppl; 1985; 91():1-44. PubMed ID: 3868029
[TBL] [Abstract][Full Text] [Related]
25. Prospective hormone study of hypothalamic-pituitary function in patients with nasopharyngeal carcinoma after high dose irradiation.
Chen MS; Lin FJ; Huang MJ; Wang PW; Tang S; Leung WM; Leung W
Jpn J Clin Oncol; 1989 Sep; 19(3):265-70. PubMed ID: 2509765
[TBL] [Abstract][Full Text] [Related]
26. Effect of thyrotropin-releasing hormone and gonadotropin-releasing hormone on serum TSH, PRL, hGH, FSH and LH in primary testicular failure and in hypogonadotrophic hypogonadism.
Szilágyi G; Szabolcs I; Vydra G; Góth M; Irsy G
Acta Med Hung; 1984; 41(4):175-83. PubMed ID: 6440114
[TBL] [Abstract][Full Text] [Related]
27. Control of prostate growth.
Coffey DS; Isaacs JT
Urology; 1981 Mar; 17(Suppl 3):17-24. PubMed ID: 6163242
[No Abstract] [Full Text] [Related]
28. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
29. [Histochemical characterization of different tissue enzymes in prostate adenomas and carcinomas].
Hajek J; Papousek F; Nemecek R; Hanselova M; Strmiska M
Acta Urol Belg; 1985; 53(1):96-100. PubMed ID: 2581425
[No Abstract] [Full Text] [Related]
30. Aberrant peptide hormones in patients with urogenital carcinomas.
Dunzendorfer U; Weber W; Drahovsky D
Eur Urol; 1979; 5(2):128-32. PubMed ID: 84758
[TBL] [Abstract][Full Text] [Related]
31. Hypophysectomy for reactivated disseminated prostatic carcinoma.
Schoonees R; Bourke RS; Reynoso G; Murphy GP; Sćhalch DS
S Afr Med J; 1972 Sep; 46(36):1278-85. PubMed ID: 4118726
[No Abstract] [Full Text] [Related]
32. The effects of androgens and estrogens on human prostatic cells in culture.
Hudson RW
Can J Physiol Pharmacol; 1981 Sep; 59(9):949-56. PubMed ID: 6170410
[No Abstract] [Full Text] [Related]
33. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
[TBL] [Abstract][Full Text] [Related]
34. Histochemical and biochemical investigation of advanced prostatic carcinoma treated with estramustine phosphate, Estracyt.
Nilsson T; Müntzing J
Scand J Urol Nephrol; 1973; 7(1):18-22. PubMed ID: 4701654
[No Abstract] [Full Text] [Related]
35. Bilateral adrenalectomy for advanced prostatic carcinoma.
Schoonees R; Schalch DS; Reynoso G; Murphy GP
J Urol; 1972 Jul; 108(1):123-5. PubMed ID: 5033992
[No Abstract] [Full Text] [Related]
36. Prostatic cancer.
Blacklock NJ
Urol Res; 1977; 5(1):1-5. PubMed ID: 324081
[No Abstract] [Full Text] [Related]
37. Proceedings: Hormones and the prostate.
Griffiths K
Br J Cancer; 1974 Aug; 30(2):187-8. PubMed ID: 4419386
[TBL] [Abstract][Full Text] [Related]
38. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.
Taşar C; Akdaş A; Kirkali Z
Int Urol Nephrol; 1986; 18(1):71-4. PubMed ID: 2424860
[TBL] [Abstract][Full Text] [Related]
39. Carcinoma of the prostate: a focal point for divergent disciplines.
Smith PH; Robinson MR; Cooper EH
Eur J Cancer (1965); 1976 Dec; 12(12):937-44. PubMed ID: 1009993
[No Abstract] [Full Text] [Related]
40. [Bromocriptine, a new therapeutic principle in prostatic adenoma and carcinoma. Basis, possibilities, limits].
Jacobi GH; Altwein JE
Dtsch Med Wochenschr; 1978 May; 103(19):827-33. PubMed ID: 77217
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
